Figure 1A



Figure 1B



Figure 1C



Figure 1D



Figure 1E



Figure 1F



Figure 2A



Figure 2B



Figure 2C



Figure 2D



Figure 3A



Figure 3B



Figure 3C



Figure 3E



Figure 3G



Figure 3D



Figure 3F



Figure 4A



Figure 4B



Figure 4C



Figure 4E



Figure 4D



Figure 4G



Figure 4F



Figure 5A



Figure 5B



Figure 5C



Figure 6A



Figure 6B



Figure 6C



Figure 7A

#	RSV F Variants
WT	DS-Cav1
1	N63R, K66E, K201E, N208R
2	K87E, Q94R, E294R
3	L160S, S182K
4	S169R, S173R, V178R
5	N262R, K272E, S275R
6	L45R, A346R
7	R429E, S436K
8	L467K, K470E
9	V384I, P389S
DG	Deglycosylated DS-Cav1 (kifunensine treated and endoH digested)

Figure 7B



Figure 7C




Inter-protomer competition
Motavizumab
D25
MPE8 binding site
Viral Membrane
Intra-protomer competition
MPE8 binding site
D25
Motavizumab
Viral Membrane

Figure 8

Figure 9


PreF-specific
PreF/PostF
PostF-specific
% mAbs
100
80
60
40
20
0
High (≤0.05 µg/mL)
Medium (>0.05 to 0.5 µg/mL)
Low (>0.5 to 5 µg/mL)
Weak/non-neutralizing (>5.0 µg/mL)
% mAbs
100
80
60
40
20
0
High (≤0.05 µg/mL)
Medium (>0.05 to 0.5 µg/mL)
Low (>0.5 to 5 µg/mL)
Weak/non-neutralizing (>5.0 µg/mL)

Figure 10A



Figure 10B



Figure 10C



Figure 11


control mAb
ADI-31675
ADI-31674
ADI-31673
ADI-31672
ADI-31330
ADI-31328
ADI-31319
ADI-31312
ADI-31381
ADI-31380
ADI-31379
ADI-31378
10
100
1000
IC50 (ng/ml)